{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-025942","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2022-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.655408+00:00","generated_at":"2026-06-23T05:36:35.295820+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Absci appoints Andreas Busch as Chief Innovation Officer; CTO Matthew Weinstock transitions to consultant","bullets":["Andreas Busch resigns from Board on Sept 30 to become Chief Innovation Officer effective Oct 4, 2022.","Former CTO Matthew Weinstock to serve as consultant after Oct 4; receives 12-month base salary severance, COBRA reimbursement, and $145,125 prorated bonus.","Dr. Busch brings R&D expertise from Sanofi, Bayer, Shire; led over 10 drugs to FDA approval.","As Chief Innovation Officer, Dr. Busch will lead R&D, technical operations, and internal/partner programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-025942","json":"https://secwatch.observer/filing/0001628280-22-025942.json","markdown":"https://secwatch.observer/filing/0001628280-22-025942.md","text":"https://secwatch.observer/filing/0001628280-22-025942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000162828022025942/0001628280-22-025942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000162828022025942/absc-20220930.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T05:36:35.295820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"64831e2318","claim":"Andreas Busch was appointed as Chief Innovation Officer at Absci Corp.","evidence_excerpt":"effective immediately upon his appointment as the Company's Chief Innovation Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672688/000162828022025942/0001628280-22-025942-index.htm","confidence":0.7,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Innovation Officer"}],"fact_type":"executive_change"},{"claim_id":"955a2e184c","claim":"Andreas Busch resigned as Director at Absci Corp.","evidence_excerpt":"he would resign from the Company's Board of Directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672688/000162828022025942/0001628280-22-025942-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e273071462","claim":"Matthew Weinstock changed role as Chief Technology Officer at Absci Corp.","evidence_excerpt":"Matthew Weinstock, Ph.D., the Company's Chief Technology Officer, will transition into a consultant role on October 4, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672688/000162828022025942/0001628280-22-025942-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned to consultant"},{"label":"Role","value":"Chief Technology Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}